Orchard Therapeutics is being bought at a massive premium

October 05, 2023 07:38 AM PDT | By Invezz

Orchard Therapeutics is being bought at a massive premium — Image source: Invezz

Details of Orchard-Kyowa definitive agreement

The Japanese specialty pharmaceutical firm is willing to spend about $387.4 million on the acquisition.

The definitive agreement values each American Depository Share (ADS) of Orchard Therapeutics at $16 – close to a 100% premium on their previous close. According to Takeyoshi Yamashita – the Chief Medical Officer of Kyowa Kirin:

Our hope is to combine with mutual respect to realise the successful creation and delivery of life-changing value for patients living with rare and life-threatening inherited diseases.

The announcement arrives more than two months after Orchard Therapeutics reported $7.3 million in revenue for its second financial quarter.

Kyowa may end up paying $17 per share instead

Orchard Therapeutics is currently awaiting U.S. approval for its treatment of metachromatic leukodystrophy that it calls OTL-200.

If approved, the unlocked “contingent value rights” will increase the overall valuation of this deal to about $477.6 million or $17 per share. Yamashita of Kyowa Kirin also said in a press release today:

With this transaction, we anticipate being able to use a new modality that can have a profound impact on patients’ lives. ORTX has already launched its HSC gene therapy in Europe.

The Japanese specialty pharmaceutical company expects this transaction to complete in the first quarter of 2024. Kyowa Kirin will get to further strengthen its leading position in genetic medicine via this merger.

The post Orchard Therapeutics is being bought at a massive premium appeared first on Invezz.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.